Amgen will partner with Novartis to co-commercialize erenumab in the U.S. while the Swiss phama giant will exclusively promote the migraine prevention drug in Canada, under a revision of a 2015 collaboration whose value remains undisclosed.
Amgen and Novartis agreed to partner on erenumab in September 2015 as part of a collaboration originally envisioned as involving joint development and commercialization of treatments in Alzheimer’s disease as well as migraine.
Last year, erenumab generated positive results in a Phase II study and two Phase III studies assessing the drug in migraine prevention. In the studies, once-monthly subcutaneous erenumab significantly reduced monthly migraine days versus placebo and demonstrated a safety profile comparable to placebo. Detailed results from the Phase III studies are being presented at the annual meeting of the American Academy of Neurology and submitted for publication.
Welcome to Clinical Research Trends, a new blog dedicated to providing breaking news on clinical trial recruitment, patient engagement, new technology and noteworthy trends. With this blog, we are working to provide clinical research organizations, sponsors and leading service providers with critical news and industry updates on a regular basis. If you want to learn more about the latest trends in clinical trial recruitment and drug development, you’ve come to the right place.